Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
HOME > BUSINESS
BUSINESS
- Teva Takeda Renamed as T’s Pharma
September 2, 2025
- FDA Clears Leqembi Autoinjector; Launch Set for Oct. 6
September 2, 2025
- Santen’s Glaucoma Drug Tapcom Launched in China
September 2, 2025
- Takeda Wins Japan Approval for Takhzyro Pen Formulation
September 2, 2025
- Specialist Highlights Lfynua’s Potential for Refractory Chronic Cough
September 1, 2025
- Medipal, JCR Expand Tie-Up to GM2 Gangliosidosis Drug JR-479
September 1, 2025
- NEC Touts AI as Core of Personalized Cancer Vaccine Development
September 1, 2025
- Meiji Bags Japan Approval for 2-Dose COVID Vaccine Vial
September 1, 2025
- Mitsubishi Tanabe Taps Ex-Pfizer Japan Chief as CEO, Ex-Takeda CFO as Chairman
August 29, 2025
- Resilire Seeks to Double Pharma Clients for Supply Chain Visualization Platform
August 29, 2025
- Novo Hooks Up with Hirosaki City on Obesity Program for Young Adults
August 29, 2025
- New PIII Breast Cancer Trial Kicks Off for Daiichi’s HER3 ADC
August 29, 2025
- Sanofi Files for Subcutaneous Formulation of Sarclisa in Japan
August 29, 2025
- BeOne’s Tevimbra Could Stand Apart in PD-1 Class with Unique Feature: Expert
August 28, 2025
- Sawai to Raise Awareness for Launch of Alcoholism Therapy App HAUDY
August 28, 2025
- Meiji Breaks Ground on “Dual-Use” Plant for Antibiotics and Vaccines
August 28, 2025
- Nihon Chouzai Shuts Down FINDAT Formulary Biz amid Tepid Demand
August 28, 2025
- Amicus’ Pompe Disease Drugs Hit Japan Market
August 28, 2025
- LP.8.1-Tailored Nuvaxovid COVID Jab Approved in Japan: Takeda
August 28, 2025
- Kringle, Keio Pair Up on HGF Therapy for Peripheral Nerve Injury
August 27, 2025
ページ
Japan is opening a new chapter in sleep medicine. The recent decision to allow medical institutions to advertise “sleep disorders”…
Let’s face it: in today’s world, changing jobs is a normal part of a successful career. But if it’s so normal, why does it feel so hard? For many people, the idea of leaving their current role brings a heavy…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…